Diamyd Medical AB (publ)
Research Diamyd Medical AB (publ) (DMYD-B) on Bullrun: market cap SEK 155.29M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerDMYD-B
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 155.29M
- Financial periodQ3 2026
- RevenueSEK 70.00K
- Net income-SEK 127.06M
- Gross margin-1271.4%
Valuation Snapshot
latest market cap is SEK 155.29M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 130.00K | -SEK 169.78M | n/a | -2853.8% | n/a | SEK 277.19M | n/a | SEK 231.63M |
| FY2024 | SEK 130.00K | -SEK 151.85M | n/a | -2753.8% | n/a | SEK 112.76M | n/a | n/a |
| FY2023 | SEK 550.00K | -SEK 116.07M | n/a | -561.8% | n/a | SEK 127.53M | n/a | n/a |
| FY2022 | SEK 450.00K | -SEK 103.52M | n/a | -877.8% | n/a | SEK 119.76M | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | SEK 155.29M | n/a | n/a | n/a |
About Diamyd Medical AB (publ)
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Diamyd Medical AB (publ)'s market cap?
Diamyd Medical AB (publ)'s market capitalization is SEK 155.29M.
What does Diamyd Medical AB (publ) do?
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. It has a research and development collaboration agreement with Juvenile Diabetes Research Foundation to develop DIAGNODE-3 Phase 3 trial in type 1 diabetes.